

RESEARCH ARTICLE

Open Access

Genetic and epigenetic silencing of the *beclin 1* gene in sporadic breast tumors

Zidong Li^{1,2,3†}, Bo Chen^{4†}, Yiqing Wu^{1,2,3}, Feng Jin⁴, Yongjing Xia^{1,2,3*}, Xiangjun Liu^{1,2,3}

Abstract

Background: Beclin 1, an important autophagy-related protein in human cells, is involved in cell death and cell survival. *Beclin 1* mapped to human chromosome 17q21. It is widely expressed in normal mammary epithelial cells. Although down-regulated expression with mono-allelic deletions of *beclin 1* gene was frequently observed in breast tumors, whether there was other regulatory mechanism of *beclin 1* was to be investigated. We studied the expression of beclin 1 and explored the possible regulatory mechanisms on its expression in breast tumors.

Methods: 20 pairs of tumors and adjacent normal tissues from patients with sporadic breast invasive ductal cancer (IDCs) were collected. The mRNA expression of *beclin 1* was detected by real-time quantitative RT-PCR. Loss of heterozygosity (LOH) was determined by real-time quantitative PCR and microsatellite methods. The protein expression of beclin 1, p53, BRCA1 and BRCA2 was assessed by immunohistochemistry. CpG islands in 5' genomic region of *beclin 1* gene were identified using MethylPrimer Program. Sodium bisulfite sequencing was used in examining the methylation status of each CpG island.

Results: Decreased *beclin 1* mRNA expression was detected in 70% of the breast tumors, and the protein levels were co-related to the mRNA levels. Expression of *beclin 1* mRNA was demonstrated to be much higher in the BRCA1 positive tumors than that in the BRCA1 negative ones. Loss of heterozygosity was detected in more than 45% of the breast tumors, and a dense cluster of CpG islands was found from the 5' end to the intron 2 of the *beclin 1* gene. Methylation analysis showed that the promoter and the intron 2 of *beclin 1* were aberrantly methylated in the tumors with decreased expression.

Conclusions: These data indicated that LOH and aberrant DNA methylation might be the possible reasons of the decreased expression of *beclin 1* in the breast tumors. The findings here shed some new light on the regulatory mechanisms of *beclin 1* in breast cancer.

Background

Autophagy is a process of cellular protein degradation through the autophagosomic-lysosomal pathway, which plays an important role in cell differentiation and maintenance of cellular homeostasis. However, it is usually defective in tumor cells [1,2]. *Beclin 1*, the mammalian orthologue of the yeast *Atg6/Vps30* gene, is the first identified tumor suppressor gene in human to mediate autophagy [3,4]. It was originally isolated by a yeast-two-hybrid screen and its protein was identified as an interacting partner of Bcl-2, an important anti-apoptosis protein [5]. Beclin 1 has a regulatory role in the process

of vesicle nucleation of autophagy [5,6]. Previous studies demonstrated that over-expression of *beclin 1* induced apoptosis via activation of caspase-9 in gastric cancer cells [7], while partial silencing of *beclin 1* aggravated apoptosis in hepatic cancer cells [8]. The different effects of *beclin 1* on cell death and cell survival in different cells depend on the cellular context.

Beclin 1 was mapped to a tumor susceptibility locus approximately 150 kb centromeric to *BRCA1* on human chromosome 17q21 [9]. Allelic loss of chromosome 17q21 is often found in human prostate, breast and ovarian cancer [10-13]. *Beclin 1* encodes an evolutionarily conserved 60 kDa coiled coil protein that is widely expressed in human normal adult tissues [9]. It has been reported that reduced levels of *beclin 1* expression and mono-allelic deletion were observed in human

* Correspondence: yjxia@mail.tsinghua.edu.cn

† Contributed equally

¹Institute of Biomedical Informatics, School of Medicine, Tsinghua University, Beijing, PR China

breast cancer cell lines and tissues [9]. Whether there are other mechanisms for the loss of *beclin 1* expression in breast cancer remains to be determined.

DNA methylation is the major epigenetic modification that involves alterations of chromatin structure. There are increasing evidences that aberrant methylation of CpG islands in 5' regulatory region of tumor suppressor gene leads to transcriptional silencing in cancer [14-16]. The human *beclin 1* gene contains a 1.5 kb CpG island from the promoter to part of the intron 2, suggesting that DNA methylation may be responsible for down-regulation of *beclin 1* expression in cancer. In addition, the promoter-associated CpG island of *beclin 1* contains E2F target site and four putative consensus Sp1 binding sites [17]. In the present study, we detected the mRNA and protein expression levels of beclin 1 and explored the possible effects of DNA methylation and LOH on decreased gene expression in breast cancer tissues. The results here provided some new insights into the regulation of *beclin 1* in breast cancer.

Methods

Tissue samples

20 pairs of tumors and adjacent normal tissues from newly diagnosed patients with sporadic breast invasive ductal cancer (IDCs) were collected from the First Affiliated Hospital of China Medical University after the approval of Institutional Review Board and patients' informed consents. All the patients were females without family hereditary breast cancer. Radio and chemo therapy was not applied to the patients before surgical operation. The patients were consecutive cases. The median age of these patients was 48.5 year-old (range, 40 - 74). The clinicopathologic parameters, including patient's age, tumor size, tumor grade, lymph node status, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-type 2 (HER2) immunoreactivity were obtained from clinical records. The tissues were obtained after surgical resection and subsequently microdissected with the assistance of pathologists. The corresponding adjacent normal tissues were derived from sites adjacent at least 1 cm away from the tumors. Tissues for immunohistochemistry use were fixed in 10% buffered formalin, embedded in paraffin, and sectioned with a microtome. Sections were stained with hematoxylin and eosin for histological examination by at least two pathologists. Tissue fragments were immediately frozen and stored in liquid nitrogen till used.

RNA extraction and quantitative reverse transcription PCR

Total RNA from tissues was extracted using TRIZOL reagent (Invitrogen) according to the manufacture's protocol. The first strand cDNA was obtained from total

RNA (0.5 µg) and oligo (dT) using the Reverse Transcription System (Promega). For real-time quantitative RT-PCR, gene specific primers and TaqMan fluorescent hybridization probes were used. β-actin was used to normalize the quantity of specific mRNA. The sequences of *beclin1* and β-actin primers are listed in Table 1. The PCR product was 85 bp for *beclin1* and 295 bp for β-actin. Their authenticity was confirmed by DNA sequencing. The amplification efficiency determined for both target and housekeeping genes was equal. Relative expression levels were calculated by the $2^{-\Delta\Delta C_t}$ method [18]. Each assay was done in triplicate.

Genomic DNA extraction and quantitative PCR

Genomic DNA of tumors and matched adjacent normal tissues was extracted with the Dneasy Tissue Kit (Qiagen). A Taqman-based quantitative PCR method using PRISM 7300 Real-Time PCR Thermal Cycler (Applied Biosystem) was applied to detect the relative copy number of beclin 1. DNA content per haploid genome was normalized to that of 18S rDNA and calculated by the $2^{-\Delta\Delta C_t}$ method [18]. Table 1 showed the sequences of the specific primer pairs and the Taqman probes. PCR products were sequenced to confirm their authenticity. Each assay was done in triplicate. A dilution series was performed to quantify primer efficiency.

Mutational and microsatellite analysis

To search for mutations of the *beclin 1* gene by polymerase chain reaction - single strand conformation polymorphism (PCR-SSCP) analysis, each of the 12 exons was amplified using its specific primers. The sequences of the primers and PCR conditions were as described by Aita et al [9]. Denatured PCR products were loaded onto non-denaturing 6% polyacrylamide gels, electrophoresed at 4°C, stained with silver staining, and visualized.

To analyze LOH of the *beclin 1* gene, a microsatellite marker on 17q21, D17S579, was selected through UniSTS database of National Center for Biotechnology Information (NCBI). Primer sequences are shown in Table 1. We defined LOH as a completely absent or significantly decreased signal intensity of one allele.

Sodium bisulfite modification and sequencing

The methylation status of the *Beclin 1* CpG island was determined by the bisulfite sequencing method [19]. 0.5~1 µg genomic DNA was digested with BamHI that does not cut within the sequence of the CpG island. DNA was denatured by 0.3 M NaOH at 42°C for 30 min. Then 3 M sodium bisulfite (Sigma) and 10 mmol/L hydroquinone were added, which was further incubated at 50°C for 16 h. Modified DNA was purified using Wizard DNA purification resin (Promega), re-treated

Table 1 Nucleotide sequences of primers used

Name	Sequence (5'→3')	Purpose
BI-F	TGCAACCTTCCACATCT	RT-PCR
BI-R	TTCCACGGGAACACTG	RT-PCR
β-actin-F	TCACCCACACTGTGCCCATCTACGA	RT-PCR
β-actin-R	CAGCGGAACCGCTCATTGCCAATGG	RT-PCR
BI-QF	TCTGCCTTCTCTGTAG	Q-PCR
BI-QR	TTCCACGGGAACACTG	Q-PCR
18S-QF	ACATCCAAGGAAGGCAGCAG	Q-PCR
18S-QR	TTCGCTACTACCTCCCCGG	Q-PCR
BI-Taqman	FAM-CACAGTGGACAGTTTGGCACAATCA-TAMRA	Q-PCR
β-actin-Taqman	FAM-CAGCCGTGGCCATCTCTTGCTCGAA-TAMRA	Q-PCR
18S-Taqman	FAM-CGCGCAAATTACCCACTCCCGA-TAMRA	Q-PCR
BI-bs1F	GTTTTTAAAGTGTGGAATTATAAG	Bisulfite first PCR
BI-bs1R	AACTCCTAATCCACAAAACACAA	Bisulfite first PCR
BI-bs1F'	TTGTTGTTGTTTTGAGATGGAGTT	Bisulfite nested PCR
BI-bs1R'	AAAAATATAAAAACAAAACC	Bisulfite nested PCR
BI-bs2F	GGGTTTGTGAGTTTGTGGATTAG	Bisulfite first PCR
BI-bs2R	AAAAAAAACCTCAATAAAAACC	Bisulfite first PCR
BI-bs2F'	AGTTTGTGATTAGGAGTTTTTGT	Bisulfite nested PCR
BI-bs2R'	TAAAAATCCCAAACCTCCTCTA	Bisulfite nested PCR
BI-bs3F	ATTTTAGAAGGGAGTTTGGGAATT	Bisulfite first PCR
BI-bs3R	TTAAACCTTCCATCCCTAAAAC	Bisulfite first PCR
BI-bs3F'	TTTTGGGTTTTAAATTGTTTTTGT	Bisulfite semi-nested PCR
BI-bs3R'	TTAAACCTTCCATCCCTAAAAC	Bisulfite semi-nested PCR
BI-bs4F	ATATTGTGGATTTTTGAGAGTTTT	Bisulfite first PCR
BI-bs4R	AAATCTTCTTTTACTACTAAAACTCTCT	Bisulfite first PCR
BI-bs4F'	TTGTAATTTTAGTATTTTGGGAGAT	Bisulfite nested PCR
BI-bs4R	CTCTATTACCCAACTAAAATACAATAATA	Bisulfite nested PCR
D17S579F	AGTCCTGTAGACAAAACCTG	Microsatellite analysis
D17S579R	CAGTTTCATACCAAGTTCCCT	Microsatellite analysis

Q-PCR, quantitative PCR.

with 0.3 M NaOH at 37°C for 15 min, precipitated with ethanol, and resuspended in 50 µL water. Semi-nested or nested PCR was used to amplify these regions. Primer sequences are detailed in Table 1. Five clones of each PCR sample were picked up and sequenced.

Immunohistochemistry

Protein expression of *beclin 1* was performed on breast tissues fixed by formalin and embedded by paraffin. Slides of 4 µm sections were deparaffinized with xylene and antigen retrieval was accomplished by heat. The sections were then incubated in 3% hydrogen peroxide at room temperature for 5 min to block endogenous peroxidase activity. Slides were then incubated with rabbit anti-beclin 1 polyclonal antibody (Cell Signaling) at 1:300 dilutions at 4°C overnight. Then rinse the slides three times in PBS for 5 m each and incubate in biotin-labeled rabbit anti-rabbit secondary antibodies for 1 h at room temperature. After washing three times with PBS, the staining was performed using 3, 3'-

diaminobenzidine. Sections were counterstained with hematoxylin. Staining was considered positive when cytoplasmic staining was observed in at least 30% of the neoplastic cells. And staining intensity was the strength of the signal and was evaluated on a scale of 0 to 2: 0, negative; 1+, weak staining; 2+, moderate/strong staining. We also compared IHC data between tumors and corresponding adjacent normal tissues by percentage of positive cells and intensity of staining to estimate the changes of beclin 1 expression.

P53 protein expression was performed using anti-p53 monoclonal antibody (Ab-8, Lab Vision Corporation), which recognized both wild type and mutant forms of the p53 protein. BRCA1 and BRCA2 protein expression were assessed using an anti-BRCA1 monoclonal antibody (Ab-1, Oncogene Research Products) and an anti-BRCA2 polyclonal antibody (Ab-2, Oncogene Research Products). Samples were considered positive when 20%, 10%, and 10% of the cells were stained with p53, BRCA1 and BRCA2, respectively.

Data analysis

Data were expressed as mean \pm standard deviation. The ratio of *beclin 1* mRNA expression in the tumor to that in the corresponding adjacent normal tissue in each case was transformed using a common logarithm. For statistical comparisons of these log-transformed data between two groups, a t-test was used. All statistical analyses were performed using SPSS software, version 10.0 (SPSS Japan Inc., Tokyo, Japan). For all of the statistical tests, a two-sided p-value of less than 0.05 was considered statistically significant.

Results

Down-regulated *beclin 1* mRNA expression in breast cancer tissues

We detected relative mRNA expression of *beclin 1* of 20 breast tumor tissues vs. corresponding normal tissues by quantitative RT-PCR. The mean \pm SD *beclin 1*/ β -actin mRNA level was 1.56 ± 1.01 for tumor tissues and 2.24 ± 1.39 for adjacent normal tissues (Table 2). As a whole, down-regulated expression of *beclin 1* was found in 14 out of 20 (70%) of the breast cancer tissues (Figure 1). Furthermore, 6 out of 20 (30%) in the breast tumors showed a significant decrease (tumor: normal tissue ratio < 0.5) of *beclin 1* mRNA expression. Meanwhile,

Table 2 *Beclin 1*/ β -actin mRNA expression in breast tissues

n = 20	<i>Beclin 1</i> / β -actin mRNA expression
Adjacent normal tissues	2.24 ± 1.39
Tumors	1.56 ± 1.01
	$p = 0.034$

Data are means \pm SD. The numbers show the mean values of *beclin 1*/ β -actin mRNA expression and standard deviation in 20 breast tumors and adjacent normal tissues. Statistical analysis was done by paired t-test.

down-regulated *beclin 1* mRNA expression was not observed in 6 out of 20 (30%) of the breast tumors compared to the corresponding normal tissues.

As was shown in Table 3, we analyzed the correlation between *beclin 1* mRNA expression and clinicopathological parameters, including age, the presence of lymphatic invasion, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-type 2 (HER2). No detectable significant difference was observed.

Immunohistochemical analysis of *beclin 1* protein expression in breast tumors

Sections of breast tumors were applied to analyze the protein expression of *beclin 1*. The staining was cytoplasmic. 13 out of 20 (65%) of tumors showed reduced *beclin 1* staining (Figure 2C, 2D) and normal epithelial cells showed strong cytoplasmic *beclin 1* expression (Figure 2A). As illustrated in Table 4, there was significant positive correlation between *beclin 1* mRNA expression and immunoreactivity in breast tumors ($p < 0.001$).

The correlation between *beclin 1* mRNA expression and p53, BRCA1 and BRCA2 protein expression in breast tumors

p53 protein over-expression was detected in 2 (10%) out of 20 breast tumors (Figure 3A, Table 5). There was no obvious excess nuclear p53 protein staining in the corresponding normal tissues, which indicates that the p53 level in the normal tissues is low (Figure 3B). BRCA1 and BRCA2 positive nuclear staining was observed in 6 (30%) and 9 (45%) out of 20 breast tumors, respectively (Figure 3B, 3D, Table 5). *Beclin 1* mRNA levels were significantly higher in the BRCA1 positive tumors than those in the BRCA1 negative ones ($p = 0.014$) (Table 6).




Figure 1 *Beclin 1* mRNA relative expression of breast tumors vs adjacent normal tissues. Quantitative RT-PCR was carried out to detect the expression of *beclin 1* with β -actin as a normalizer.

Table 3 Correlation between *beclin 1* mRNA expression in breast cancer and clinicopathologic parameters

	Case number	Average of log T/N	Standard deviation of log T/N	P-value
Age (y)				
50	11	-0.13	0.06	0.160
≥50	9	-0.30	0.07	
Lymphatic invasion				
Positive	8	-0.23	0.06	0.356
Negative	11	-0.13	0.05	
ER				
Positive	7	-0.31	0.08	0.199
Negative	13	-0.15	0.06	
PR				
Positive	10	-0.20	0.06	0.905
Negative	10	-0.21	0.09	
HER2				
Positive	19	-0.21	0.07	-
Negative	1	-0.07	-	

T, tumors; N, normal tissues; -, not applied.




Figure 2 Immunohistochemical analysis of beclin 1 expression in breast tissues. Photographs were taken at × 200 magnification. A brown color represents positive staining of beclin 1. Counterstaining of nuclei was performed with hematoxylin as a blue color. (A) Positive staining of beclin 1 in adjacent normal breast epithelial cells; (B) Positive staining of beclin 1 in a breast tumor; (C) Weak immunoreactivity of beclin 1 in a breast tumor; (D) Negative control of beclin 1 staining in a breast tumor.

Table 4 Comparison between *beclin 1* mRNA and protein expression in breast cancer

Beclin 1 mRNA expression (Quantitative RT-PCR)	Beclin 1 protein expression (IHC)	
	Positive	Negative
Positive (6)	6	0
Negative (14)	1	13
$p < 0.001$		

Positive means that the expression level of *beclin 1* mRNA/protein in breast tumors increased compared with the corresponding adjacent normal tissues. And negative means that the expression level of *beclin 1* mRNA/protein in breast tumors decreased compared with the corresponding adjacent normal tissues. The association between *beclin 1* mRNA and protein expression was analyzed using the χ^2 test.

LOH of *beclin 1* was detected in some of the breast cancer tissues

Using quantitative PCR method, *beclin 1* gene copy number was detected in all breast tissues. As was shown in Table 5, LOH was found in 11 out of 20 (55%) of breast tumors (tumor/normal < 1.0). Meanwhile, we applied a microsatellite marker, D17S579 [10], to validate the sensitivity of this methodology. LOH was verified in 9 out of 20 (45%) of breast tumors (Figure 4, Table 5). Table 7 compared the correlation between both methods for LOH analysis. The results showed a significant relationship ($p < 0.001$) between both methods, which exhibited accordance in 90% of cases.

CpG island analysis in *beclin 1* regulatory region

Previous studies reported that *beclin 1* maps to 17q21 that spans over 12 kb locus of human genome (Figure 5A) [9]. The 70 kb region of genome in which the *beclin 1* gene resides, contains a moderate number of genes (Figure 5B). Telomerically flanking the *beclin 1* gene is the *PSME3* gene, a member of the *PA28* family, which binds specifically to 20 S proteasomes and stimulates the hydrolysis of peptides [20], and the *AOC2* gene, a member of the copper-binding amine oxidase super family, which is an important regulator of cellular polyamine levels [21]. Centromerically flanking *beclin 1* is the *WNK4* gene, known to regulate thiazide-sensitive Na-Cl co-transport [22], and the other two genes, *CNTD1* and *CCDC56* with unknown functions. *Beclin* gene is composed of 12 exons and exon 2 encodes the translational initial codon (ATG) (Figure 5C). 5' region of the *beclin 1* gene was inspected by the MethPrimer program <http://www.urogene.org/methprimer>. The data showed this region of the genome to be a CG rich (Figure 5D). The CpG island encompassed from the promoter to the intron 2 (nt -528 to 977). Because aberrant cytosine methylation within 5' end of tumor suppressor genes is commonly observed in cancer cells [23,24], *beclin 1* was likely a candidate gene for epigenetic silencing.

Certain CpG dinucleotides in the promoter and the intron 2 of the *beclin 1* gene were methylated in breast tumors

There are genetic and epigenetic alterations for the down-regulation of many genes. To identify mutations in the *beclin 1* gene in breast cancer, mutational analysis was carried out by PCR-SSCP in genomic DNA of 20 breast tumors. No mutation was found in 12 exons of the *beclin 1* gene in 20 breast tumors. As mentioned above, there was a large and dense CpG island ranging from the promoter to the intron 2 of the *beclin 1* gene. Therefore, we first detected the methylation status of the CpG islands in the 6 breast tumors with significantly down-regulated *beclin 1* expression and corresponding normal tissues by bisulfite sequencing. In the promoter from -528 to -65 (from transcription start site) and the intron 2 from 733 to 977, methylation was detected in 4 tumors (T3, 8, 16, 20) and weakly detected in the corresponding normal tissues. In the other two samples (T1, 12) with significantly down-regulated *beclin 1* expression and LOH, methylation was weakly detected in both tumors and corresponding normal tissues. Then we tested another 6 cases, whose *beclin 1* mRNA expression was not down-regulated in breast tumors, and methylation was weakly or hardly detected in both tumors and normal tissues (Figure 6).

Discussion

It has been reported that tumor suppressor genes with high frequencies of LOH in human chromosomal region 17q21 and epigenetic silencing, are important in hereditary and sporadic breast cancer tumorigenesis [25,26]. One of these genes is *BRCA1*, whose decreased expression was often observed in breast cancer with epigenetic silencing and mono-allelic deletion of the *BRCA1* gene [27-29]. In the present study, we showed that the mRNA and protein expression of *beclin 1*, another 17q21 gene, was frequently down-regulated in breast tumors. This down-regulation in some tumors was due to allele loss in gene copy number and in some others was due to DNA methylation. There was no significant association between *beclin 1* mRNA expression and clinicopathologic parameters.

P53, *BRCA1* and *BRCA2* are clearly involved in the development of both sporadic and hereditary breast cancers [30-34]. Mutations of these genes are the most common genetic variations and are widely distributed in breast cancer cells. Tumors with missense mutations displayed positive nuclear immunoreactivity of p53 for the effect of mutation on the prolongation of p53 half-life through increased protein stability [35]. Cancers with wild-type P53, including breast cancer [35], are generally negative for p53 immunoreactivity due to the rapid degradation of normal p53 protein. Meanwhile, loss or reduction of *BRCA1* and *BRCA2* expression has




Table 5 Beclin 1 mRNA and protein expression, p53, BRCA1 and BRCA2 protein expression and LOH analysis of beclin 1 in breast cancer tissues

Breast cancer cases	Beclin 1 mRNA expression	Protein expression				LOH (Q-PCR)	LOH (microsatellite)
		Beclin 1	P53	BRCA1	BRCA2		
1	-	-	-	-	-	+	+
2	+	+	-	+	+	-	-
3	-	-	-	-	-	+	+
4	-	+	-	-	+	+	+
5	+	+	-	+	-	-	-
6	-	-	-	+	+	+	+
7	-	-	-	+	+	+	+
8	-	-	-	-	-	+	+
9	+	+	-	-	-	-	-
10	-	-	-	+	-	-	-
11	+	+	+	-	+	+	+
12	-	-	-	-	-	+	+
13	-	-	-	-	+	+	+
14	-	-	-	-	-	+	+
15	+	+	-	-	-	-	-
16	-	-	-	-	-	-	-
17	+	+	+	+	+	+	-
18	-	+	-	-	-	-	-
19	-	-	-	-	+	-	-
20	-	-	-	-	+	-	-

"+": positive; "-": negative.

Table 6 Relationship between beclin 1 mRNA expression and immunohistochemical characterization of p53, BRCA1 and BRCA2 in breast IDCs

	Case number	Average of log	Standard deviation	P-value
	(%)	T/N	of log T/N	
<i>p53</i>				
Positive	2 (10)	-0.24	0.24	0.798
Negative	18(90)	-0.20	0.06	
<i>BRCA1</i>				
Positive	6 (30)	-0.01	0.02	0.014*
Negative	14 (30)	-0.31	0.08	
<i>BRCA2</i>				
Positive	9 (45)	-0.16	0.04	0.483
Negative	11 (55)	-0.24	0.10	

No obvious nuclear p53 protein staining was defined as negative and over-expression of p53 was defined as positive. Loss or reduction of BRCA1 and BRCA2 expression was defined as negative in tumors compared with the paired normal tissue, and vice versa.

been exhibited in sporadic breast cancers [36]. Immunohistochemistry of p53 and BRCA1/2 proteins in tumor cells may be useful as an additional method in exploring the relationship between the beclin 1 expression levels and the status of these important tumor suppressor genes in breast cancer. Therefore, we examined their expression levels by immunohistochemical staining in 20 breast tumors. By IHC staining of p53 protein, we




Figure 4 Representative photograph showing LOH in breast cancer. Above graph, microsatellite marker; under graph, patient's number; arrowheads, the allele losses; N, normal DNA; T, tumor DNA.

Table 7 Comparison between microsatellite and quantitative – PCR method for LOH analysis of the *beclin 1* gene in 20 paired tissues

Q-PCR	D17S579	
	Negative	Positive
Positive (13)	2	11
Negative (7)	7	0


$p < 0.001$


D17S579 was a microsatellite marker located in 17q21. Comparison was analyzed using the χ^2 test.

found 2 cases (T11 and T17) exhibited more than 50% positive nuclear staining cells of all tumor cells. IHC over-expression of p53 might reflect that genetic alterations also occurred in these tumors. We further analyzed the correlation between *beclin 1* expression and p53 over-expression and no obvious association was obtained. It is known that the normal BRCA1 protein plays an important role in repairing breaks in DNA [37].

However, when *BRCA1* exhibited loss of expression due to genetic or epigenetic alterations, abnormal repair function of *BRCA1* may lead to DNA replication errors and cancerous growth [38,39]. Liang *et al* [3] reported that *beclin 1* played a negative regulatory role in mammary cell growth and tumorigenesis using gene-transfer techniques. Our data showed that *beclin 1* expression was significant higher in the *BRCA1* positive tumors than in the negative ones, suggesting *beclin 1* expression may be related to cell growth in breast cancer.

Beclin 1 is mapped to a region approximately 150 kb to *BRCA1* on chromosome 17q21, which is usually deleted in breast, ovarian and prostate cancer [8-11]. LOH at the *beclin 1* locus was observed in 9 out 22 (41%) of the breast cancer cell lines [9]. In the present study, all examined tumors exhibited a LOH rate of at least 45% at the *beclin 1* locus and no mutation was found in the coding regions of *beclin 1*. These results confirmed that frequent allelic losses of *beclin 1* were part of reasons for *beclin 1* down-regulation and





mutations were unlikely the main regulatory mechanism for *beclin 1* inactivation in breast cancer. Meanwhile, allelic loss of *beclin 1* was only found in a portion of the breast tumors with down-regulated expression, indicating that mechanisms other than allelic deletion may be responsible for the decreased mRNA expression.

The CpG island in *beclin 1* spans over 1.5 kb from the promoter to the intron 2 [nucleotide (nt) -528 to 977] with the transcription start site defined as +1, so it is divided into four regions to be cloned. The first region contained part of the *beclin 1* promoter from -528 to -65. The second region was located between -83 and 164 from the proximal promoter to part of the first

intron. The third region laid between 137 and 400 from a portion of the first intron to part of the second exon. The fourth region was situated between 733 and 977 from a portion of the second intron. We found that certain CpG dinucleotides at the promoter and the intron 2 of the *beclin 1* gene are hypermethylated in breast tumors. As dense methylation of the 5' CpG islands was not detected in normal tissues, we speculated that this methylation patterns in tumor cells were aberrant and disease associated. As a whole, the regulation of *beclin 1* expression was a little complicated. In some cases, T16 and T20, the decreased expression was due to aberrant DNA methylation; While in T1 and T12, the decrease was from LOH; And in the other cases, T3 and T8, both aberrant DNA methylation and LOH devoted to the decreased expression of *beclin 1* (Table 8). For this reason, different mechanisms seemed to be involved in the regulation of *beclin 1* expression.

Some tumors (T10 and T19) with low expression of *beclin 1* did not have either LOH or methylation. Other identified mechanisms might contribute to the regulation of *beclin 1* expression, such as bcl-2 overexpression [40]. Recently, a novel *beclin 1* binding protein, UVRAG, was found to positively regulate autophagy signaling pathway mediated by *beclin 1* in colon cancer [41]. Exploring different involving factors that could affect the regulatory expression of *beclin 1* might contribute to the pathogenesis of human cancers.

Aberrant methylation of 5' CpG islands associated with down-regulated mRNA expression of *beclin 1* indicated that methylation might be a new mechanism for loss of expression of *beclin 1*, which has not been shown previously. Sequence analysis revealed that there were four putative consensus Sp1 binding sites at the promoter [17] and one putative Sp1 binding site at the intron 2, which share high sequence homology to the consensus Sp1 motif. It has been reported that aberrant DNA hypermethylation in the promoter of a gene can silence its expression [42], and that methylation in the introns can silence or enhance its expression [43-45]. Whether DNA methylation in the promoter and the

intron 2 of *beclin 1* affects the binding affinity of transcriptional factor needs to be further determined.

Conclusions

In conclusion, our studies confirmed that down-regulation of *beclin 1* expression is present in breast cancer. Other than deletion in gene copy number, DNA hypermethylation in the promoter and/or intron 2 may be a new mechanism responsible for down-regulation of *beclin 1* expression. Since *beclin 1* has important functions in apoptosis and autophagy, its epigenetic modification might provide new targets for cancer therapy.

Acknowledgements

This project is supported by Tsinghua-Yue-Yuen Medical Sciences Fund, Foundation for the Mainstay Talents of Tsinghua University, National Natural Science Foundation of China (NSFC) Grants 30670851, Wu Shunde Medical Science Research Fund and the Key Project of Chinese Ministry of Education (No. 03180), Foundation of Science and Technology Bureau of Liaoning Province of China (No. 20061038), Foundation of Educational Commission of Liaoning Province of China (No. 2008762).

Author details

¹Institute of Biomedical Informatics, School of Medicine, Tsinghua University, Beijing, PR China. ²Department of Biological Science and Biotechnology, Tsinghua University, Beijing, PR China. ³Ministry of Education Key Laboratory of Bioinformatics, Tsinghua University, Beijing, PR China. ⁴Department of Surgical Oncology, The First Affiliated Hospital, China Medical University, Shenyang, PR China.

Authors' contributions

LZD carried out molecular biological studies, participated data collection, analysis and the preparation of the manuscript. CB and JF collected tissue samples and participated in the clinical part of the study and immunohistochemistry. WYQ, XYJ and LXJ supervised the project and overviewed the analysis of the data and the manuscript. All authors have read and approved the present manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 15 February 2009 Accepted: 16 March 2010

Published: 16 March 2010

References

- Edinger AL, Thompson CB: Defective autophagy leads to cancer. *Cancer Cell* 2003, **4**:422-424.
- Klionsky DJ, Emr SD: Autophagy as a regulated pathway of cellular degradation. *Science* 2000, **290**:1717-1721.
- Liang XH, Jaskon S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B: Induction of autophagy and inhibition of tumorigenesis by *beclin 1*. *Nature* 1999, **402**:672-676.
- Yue Z, Jin S, Yang C, Yang C, Levine B: *Beclin 1*, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. *Proc Natl Acad Sci* 2003, **100**:15077-15082.
- Liang XH, Kleeman LK, Jiang HH, Gordon G, Goldman JE, Berry G, Herman B, Levine B: Protection against fatal Sindbis virus encephalitis by *Beclin*, a novel Bcl-2 interacting protein. *J Virol* 1998, **72**:8586-8596.
- Liang XH, Yu J, Brown K, Levine B: *Beclin 1* contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function. *Cancer Res* 2001, **61**:3443-3449.
- Furuya D, Tsuji N, Yagihashi A, Watanabe N: *Beclin 1* augmented cis-diamminedichloroplatinum induced apoptosis via enhancing caspase-9 activity. *Exp Cell Res* 2005, **307**:26-40.

Table 8 Summary of LOH and aberrant DNA methylation in breast tumors showing down – regulated expression of *beclin 1*

No.	LOH	DNA Methylation
1	+	-
3	+	+
8	+	+
12	+	-
16	-	+
20	-	+

8. Daniel F, Legrand A, Pessayre D, Vadrot N, Descatoire V, Bernuau D: **Partial Beclin 1 silencing aggravates doxorubicin- and Fas-induced apoptosis in HepG2 cells.** *World J Gastroenterol* 2006, **12**:2895-2900.
9. Aita VM, Liang XH, Murty WV, Pincus DL, Yu WP, Cayanis E, Kalachikov S, Gilliam TC, Levine B: **Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21.** *Genomics* 1999, **59**:59-65.
10. Russell SE, Hickey GI, Lowry WS, White P, Atkinson RJ: **Allele loss from chromosome 17 in ovarian cancer.** *Oncogene* 1990, **7**:2069-2072.
11. Sato T, Saito H, Morita R, Koi S, Lee JH, Nakamura Y: **Allelotype of human ovarian cancer.** *Cancer Res* 1991, **51**:5118-5122.
12. Futreal PA, Soderkvist P, Marks JR, Iglehart JD, Cochran C, Barrett JC, Wiseman RW: **Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms.** *Cancer Res* 1992, **52**:2624-2627.
13. Gao X, Zacharek A, Salkowski A, Grignon DJ, Sakr W, Porter AT, Honn KV: **Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer.** *Cancer Res* 1995, **55**:1002-1005.
14. Miremadi A, Oestergaard MZ, Paul PD, Caldas C: **Cancer genetics of epigenetic genes.** *Hum Mol Genet* 2007, **16**:28-49.
15. Widschwendter M, Jones PA: **The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer.** *Clin Cancer Res* 2002, **8**:17-21.
16. Esteller M, Corn PG, Baylin SB, Herman JG: **A gene hypermethylation profile of human cancer.** *Cancer Res* 2001, **61**:3225-3229.
17. Weinmann AS, Bartley SM, Zhang T, Zhang MQ, Farnham PJ: **Use of chromatin immunoprecipitation to clone novel E2F target promoters.** *Mol Cell Biol* 2001, **21**:6820-6832.
18. Livak KJ, Schmittgen TD: **Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C_T}$ method.** *Methods* 2001, **25**:402-408.
19. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: **Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands.** *Proc Natl Acad Sci* 1996, **93**:9821-9826.
20. Roessler M, Rollinger W, Mantovani-Endl L, Roessler M, Rollinger W, Mantovani-Endl L, Hagemann ML, Palme S, Berndt P, Engel AM, Pfeffer M, Karl J, Bodenmüller H, Rüschoff J, Henkel T, Rohr G, Rossol S, Rösch W, Langen H, Zolg W, Tacke M: **Identification of PSME3 as a Novel Serum Tumor Marker for Colorectal Cancer by Combining Two-dimensional Polyacrylamide Gel Electrophoresis with a Strictly Mass Spectrometry-based Approach for Data Analysis.** *Mol Cell Proteomics* 2006, **5**:2092-2101.
21. Zhang Q, Mashima Y, Noda S, Y Imamura, Kudoh J, Shimizu N, Nishiyama T, Umeda S, Oguchi Y, Tanaka Y, Iwata T: **Characterization of AOC2 gene encoding a copper-binding amine oxidase expressed specifically in retina.** *Gene* 2003, **318**:45-53.
22. Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP: **Molecular pathogenesis of inherited hypertension with hyperkalemia: The Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4.** *Proc Natl Acad Sci USA* 2003, **100**:680-684.
23. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM: **Predicting aberrant CpG island methylation.** *Proc Natl Acad Sci* 2003, **100**:12253-12258.
24. Ushijima T: **Detection and interpretation of altered methylation patterns in cancer cells.** *Nat Rev Cancer* 2005, **5**:223-231.
25. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC: **Analysis of Loss of Heterozygosity in 399 Premalignant Breast Lesions at 15 Genetic Loci.** *J Natl Cancer Inst* 1998, **90**:697-703.
26. Dobrovic A, Simpfordorfer D: **Methylation of the BRCA1 Gene in Sporadic Breast Cancer.** *Cancer Res* 1997, **57**:3347-3350.
27. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu JH, Fackenthal J, Tretiakova M, Das S, Olopade OI: **BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.** *Cancer Res* 2005, **65**:10692-10699.
28. Rice JC, Massey-Brown KS, Futscher BW: **Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells.** *Oncogene* 1998, **17**:1807-1812.
29. Mueller CR, Roskelley CD: **Regulation of BRCA1 expression and its relationship to sporadic breast cancer.** *Breast Cancer Res* 2002, **5**:45-52.
30. Coles C, Condie A, Chetty U, Steel M, Evans HJ, Prosser J: **P53 mutations in breast cancer.** *Cancer Res* 1992, **52**:5291-5298.
31. Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD: **TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.** *Cancer Res* 2001, **61**:4092-4097.
32. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, Vijver MJ, Farid LM, Venter D, Antoniou A, Storfes-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, Mcmanus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Easton DF: **Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.** *J Natl Cancer Inst* 1998, **90**:1138-1145.
33. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR, Futreal A: **BRCA2 mutations in primary breast and ovarian cancers.** *Nat Genet* 1996, **13**:238-240.
34. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihnsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS: **Accumulation of p53 Tumor Suppressor Gene Protein: An independent marker of prognosis in breast cancers.** *J Natl Cancer Inst* 1992, **84**:845-855.
35. Hedenfalk I, Duggan D, Chen YC, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J: **Gene-expression profiles in hereditary breast cancer.** *N Engl J Med* 2001, **344**:344-359.
36. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ: **Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.** *Nat Genet* 1999, **21**:236-240.
37. Welch PL, Owens KN, King MC: **Insights into the functions of BRCA1 and BRCA2.** *Trends Genet* 2000, **16**:69-74.
38. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA: **BRCA1 required for transcriptioncoupled repair of oxidative DNA damage.** *Science* 1998, **281**:1009-1012.
39. XL X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng CX: **Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.** *Nat Genet* 1999, **22**:37-43.
40. Pattinire S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B: **Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy.** *Cell* 2005, **122**:927-39.
41. Liang C, Feng P, Ku B, Dotan I, Canaan D, Oh BH, Jung JU: **Autophagic and tumor suppressor activity of a novel Beclin 1-binding protein UVRAG.** *Nat Cell Biol* 2006, **8**:688-698.
42. Herman JG, Baylin SB: **Gene silencing in cancer in association with promoter hypermethylation.** *N Engl J Med* 2003, **349**:2042-2054.
43. Douglas DB, Akiyama Y, Carraway H, Belinsky SA, Esteller M, Gabrielson E, Weitzman S, Williams T, Herman JG, Baylin SB: **Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer.** *Cancer Res* 2004, **64**:1611-1620.
44. Unoki M, Nakamura Y: **Methylation at CpG islands in intron 1 of EGR2 confers enhancer-like activity.** *FEBS Lett* 2003, **554**:67-72.
45. Cheng CK, Chow WC, Loo TY, Chan TK, Chan V: **The cell cycle checkpoint gene Rad9 is a novel Oncogene activated by 11q13 amplification and DNA methylation in breast cancer.** *Cancer Res* 2005, **65**:8646-8654.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2407/10/98/prepub>

doi:10.1186/1471-2407-10-98

Cite this article as: Li et al.: Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors. *BMC Cancer* 2010 **10**:98.